Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: One of the main consequences of inhibition of neovessel growth produced by angiogenesis inhibitors is increased intratumor hypoxia. Growing evidence indicates that tumor cells escape from this hypoxic environment to better nourished locations, presenting hypoxia as a positive stimulus for invasion. Particularly, anti-VEGF/R therapies produce hypoxia-induced invasion and metastasis in a spontaneous mouse model of pancreatic neuroendocrine cancer, RIP1-Tag2.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author: Casanovas O
Authors: Zuazo-Gaztelu I, Pàez-Ribes M, Carrasco P, Martín-Mitjana L, Sallaberry J,
Keywords: Antiangiogenic therapies, Semaphorin 4D, Mouse models of NETs, Invasion and metastasis,
Introduction: Pancreatic neuroendocrine tumors (PNETs) are a heterogeneous group of neuroendocrine neoplasms with distinct biological behaviour and response to treatment. Previous reports indicate that the infiltration of tumor-associated macrophages (TAMs) in PNETs strongly correlates with proliferation and metastases.
Conference: 12th Annual ENETSConcerence (2015)
Presenting Author: Krug S
Authors: Krug S, Abbassi R, Rinke A, Griesmann H, Gress T,
#127 Sunitinib for the treatment of advanced, progressive pancreatic neuroendocrine tumors
Introduction: Sunitinib is an oral, multitargeted tyrosine kinase inhibitor approved for use in advanced renal cell carcinoma and imatinib-resistant/intolerant gastrointestinal stromal tumors. Investigations of sunitinib in the RIP1-Tag2 mouse model and in phase I/II clinical trials provide evidence of antitumor activity against pancreatic neuroendocrine tumors (NET).
Conference: 7th Annual ENETSConcerence (2010)
Presenting Author: Raymond E
Authors: Raymond E, Seitz J, Bang Y, Borbath I, Lombard-Bohas C,
Keywords: Sunitinib, phase III, pancreatic neuroendocrine tumor ,